Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
-
Published:2022-02
Issue:1
Volume:20
Page:11-16
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Curran CatherineORCID,
Adib ElioORCID,
Kazakova VeraORCID,
Grivas Petros,
Diamantopoulos Leonidas Nikolaos,
Alva Ajjai Shivaram,
Su ChristopherORCID,
Jain Rohit K.,
Tandon Ankita,
Necchi Andrea,
Marandino Laura,
Plastini Trisha M.ORCID,
Merchan Jaime R.,
Sonpavde GuruORCID
Reference20 articles.
1. Cancer Statistics, 2021;Siegel;CA Cancer J Clin,2021
2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005
3. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J Clin Oncol,2012
4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017
5. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献